Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 8/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 0.71 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24336620 | 1.00 | FLT3 (1.00) | FLT3PDGFRACDK2CCNE1SRC | |
| SCHEMBL24094072 | 0.93 | PDGFRA (0.86) | FLT3PDGFRACDK2CCNE1SRC | |
| SCHEMBL5193682 | 0.88 | FLT3 (1.00) | FLT3PDGFRACDK2CCNE1SRC | |
| SCHEMBL5193689 | 0.88 | FLT3 (1.00) | FLT3PDGFRACDK2CCNE1SRC | |
| Hydrochloric Acid SCHEMBL5195535 | 0.87 | FLT3 (0.98) | FLT3PDGFRACDK2CCNE1SRC | |
| Hydrochloric Acid SCHEMBL5195542 | 0.87 | FLT3 (0.98) | FLT3PDGFRACDK2CCNE1SRC | |
| SCHEMBL23468404 | 0.85 | PDGFRA (0.79) | FLT3PDGFRACDK2CCNE1 | |
| SCHEMBL23468402 | 0.85 | PDGFRA (0.73) | FLT3PDGFRACDK2CCNE1SRC | |
| SCHEMBL21880403 | 0.84 | FLT3 (0.78) | FLT3PDGFRA | |
| SCHEMBL5193120 | 0.84 | FLT3 (0.85) | FLT3PDGFRACDK2CCNE1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022062357-A1 | MEDICINE FOR TREATING OR PREVENTING DISEASES RELATED TO ACTIVITY OF LRRK2 KINASE OR ABNORMAL LRRK2 MUTANT KINASE | 广州智睿医药科技有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2021-06-08 | — | — | US | disclosed |
| CN-112043710-A | Medicine for treating or preventing diseases related to LRRK2 kinase or abnormal LRRK2 mutant kinase activity | 广州智睿医药科技有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200087306-A1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087306-A1 | 2,6-DISUBSTITUTED-9-CYCLOPENTYL-9H-PURINES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS | FLT3, CDK9, CDK6 | FLT3 1/4885PDGFRA 9/4885CDK2 4/4885 |
| US-11028087-B2 | 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions | FLT3, CDK9, CDK6 | FLT3 1/4885PDGFRA 9/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.